Ace Therapeutics has extensive hands-on experience in developing diagnostic technologies for drug-induced liver injury (DILI). Based on our professional scientists and advanced technology platform, we will provide the most professional and appropriate services for our global clients' diagnostic technology development projects. We are constantly working to facilitate the smooth development of your research projects.
Effective diagnosis of DILI allows patients to quickly identify the cause of liver injury while saving time and public resources in the hospital for diagnosis and treatment. Current research on biomarkers of DILI is mainly focused on acetaminophen (APAP) -induced DILI, but many other drug-induced DILI is still poorly understood.
What Can We Do?
With years of experience and multiple validations, we have established a one-stop solution for the development of DILI diagnostic technologies. We facilitate the smooth development of your research projects through our comprehensive and scientific services. If we are fortunate to cooperate, we will provide you with a high-quality data analysis platform, a fast analysis cycle, and a high-quality result report.
- Discovery of DILI Biomarkers
To date, the only major biomarker proposed for the diagnosis of DILI is protein-derived APAP-cysteine (APAP-CYS), which can contribute to the diagnosis of APAP overload. We offer comprehensive services to discover additional DILI biomarkers with a view to their use in the development of diagnostic tools.
- We offer different DILI cell and animal models for the discovery of different DILI biomarkers.
- We will perform high throughput screening of biomarkers in DILI models by gene microarray technology and protein microarray technology.
- Better DILI biomarkers will be identified through scientific and accurate analysis of the assay results.
- Diagnostic Technology Development for DILI
The same is true for DILI, where a single biomarker is often unable to accurately diagnose the disease. We will test the diagnostic role of DILI biomarkers in different experimental models of DILI by combining them in different ways so that we can develop better diagnostic tools.
In addition, we have been working on predicting the liver safety of the drugs to be tested by means of computer modeling. Through continuous communication and exploration, our computer scientists and hepatology scientists have figured out a perfect modeling approach, and we are also optimizing and improving the evaluation indexes in order to obtain more accurate diagnostic results.
Excellent experts in different fields and rich practical experience make Ace Therapeutics an important partner in the development of diagnostic technologies for DILI. We keep pace with the times and constantly improve our knowledge system and technology base to provide the most professional and scientific solutions for your research projects. If you would like to learn more about our services, please feel free to contact us.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
